- Home
- PROV vs BMEA Comparison
PROV vs BMEA Comparison
Compare PROV & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PROV
- BMEA
- Stock Information
- Founded
- PROV 1956
- BMEA 2017
- Country
- PROV United States
- BMEA United States
- Employees
- PROV N/A
- BMEA N/A
- Industry
- PROV Savings Institutions
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- PROV Finance
- BMEA Health Care
- Exchange
- PROV Nasdaq
- BMEA Nasdaq
- Market Cap
- PROV 107.5M
- BMEA 125.4M
- IPO Year
- PROV 1996
- BMEA 2021
- Fundamental
- Price
- PROV $14.26
- BMEA $2.46
- Analyst Decision
- PROV Hold
- BMEA Buy
- Analyst Count
- PROV 1
- BMEA 13
- Target Price
- PROV $16.00
- BMEA $27.92
- AVG Volume (30 Days)
- PROV 5.6K
- BMEA 539.0K
- Earning Date
- PROV 04-28-2025
- BMEA 05-01-2025
- Dividend Yield
- PROV 3.93%
- BMEA N/A
- EPS Growth
- PROV N/A
- BMEA N/A
- EPS
- PROV 0.91
- BMEA N/A
- Revenue
- PROV $38,443,000.00
- BMEA N/A
- Revenue This Year
- PROV $2.30
- BMEA N/A
- Revenue Next Year
- PROV $9.89
- BMEA N/A
- P/E Ratio
- PROV $15.67
- BMEA N/A
- Revenue Growth
- PROV N/A
- BMEA N/A
- 52 Week Low
- PROV $12.01
- BMEA $2.35
- 52 Week High
- PROV $16.70
- BMEA $18.40
- Technical
- Relative Strength Index (RSI)
- PROV 25.11
- BMEA 27.73
- Support Level
- PROV $12.98
- BMEA $2.35
- Resistance Level
- PROV $14.85
- BMEA $2.98
- Average True Range (ATR)
- PROV 0.42
- BMEA 0.25
- MACD
- PROV -0.12
- BMEA -0.02
- Stochastic Oscillator
- PROV 43.84
- BMEA 8.30
About PROV Provident Financial Holdings Inc.
Provident Financial Holdings Inc is a holding company of Provident Savings Bank, F.S.B. Through the bank, it is engaged in providing community and mortgage banking services to consumers and small to mid-sized businesses in the Inland Empire region of Southern California. The company's business segment is Bank. The Bank's activities include attracting deposits, offering banking services, and originating and purchasing single-family, multi-family, commercial real estate, construction, and other mortgage loans and, to a lesser extent, commercial business and consumer loans held for investment.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.